Edwards et al. linked EPHA2 overexpression with metastatic disease and dismal prognosis [45] and Youngblood et al. the overexpression of its phosphorylated form (pS897) with shorter survival in patients that present with lymph node metastases [46]. Here, EPHA2 is linked to metastatic malignant neoplasm in the lymph nodes.